2014-2015 Board of Directors Elected Officers
Daniel C. Malone, RPh, PhD
Daniel C. Malone, RPh, PhD, is a Professor of Pharmacy at the University of Arizona, College of Pharmacy, with cross appointment in the Mel and Enid Zuckerman College of Public Health and a Full member of the Arizona Cancer Center at the University of Arizona. Dr. Malone leads the Comparative Effectiveness Research Group at the University of Arizona and is the former Director of Pharmaceutical Policy and Outcomes with the Center for Health Economics and Outcomes Research. He was the Director of the Pharmaceutical Outcomes Research Core of the Arizona Center for Education and Research on Therapeutics. Dan has served ISPOR in many ways. He was the Program Chair for the ISPOR 15th Annual International Meeting, 2010, and is the current Research Excellence Awards Chair for the ISPOR Awards Committee. He has previously served as the Chair of the Awards Committee and as a member ISPOR Distance Education Committee. Dr. Malone has served as peer reviewer of scientific abstracts and workshop programming.
Dr. Malone recently completed a U.S. Agency for Healthcare Research and Quality (AHRQ) funded study to disseminate comparative effectiveness research to pharmacy and therapeutic committees. He has conducted and published cost-effectiveness analyses, burden-of-illness studies, patient reported outcomes studies, and numerous evaluations of healthcare interventions in real-world environments. Dan has over 120 peer-review research publications and has obtained over $15 million in extramural funds for his research programs.
Dan joined the University of Arizona in 1999 after serving as an assistant professor at the University of Colorado Health Sciences Center. He obtained his Bachelor of Science degree (magna cum laude) from the University of Colorado Health Sciences Center, and earned his MS and PhD degrees from The University of Texas at Austin. Following his formal studies Dan moved to Seattle for an Agency for Healthcare Research and Quality supported post-doctoral fellowship at the University of Washington.
ISPOR Vision Statement by Daniel C. Malone, RPh, PhD
My vision for ISPOR is to: 1) further the global development of student chapters and network; 2) build relationships between ISPOR members and healthcare decision makers; and 3) promote the generation of scientific evidence to improve health. ISPOR is a relatively new scientific organization, but the reach and impact of the Society on science and health has been amazing. As president of this prestigious organization I will continue our collaborative efforts to promote the mission and vision of the association. The future of ISPOR lies in the hands of our students and trainees. Growth in the number of ISPOR Student Chapters and developing regional networks are key to the long-term success of ISPOR. My plan is to continue quality ISPOR Short Courses offered at meetings but also expand our distance educational opportunities – especially through the student network. Another vision activity is improving the translation of our research into practice.
As president of ISPOR I will strive to build relationships between ISPOR members and those who implement health policy, especially other professional societies and payer groups. Enhancing this collaboration is key to ensure that resources wisely used while simultaneously improving health. I strongly support the Society's Good Practice Task Force Reports and will promote the continuing development of these reports to promote the use of state-of-the-art techniques for studies that address the value of healthcare. Outcomes researchers should be engaging stakeholders throughout the life-cycle of the research process – from concept to implementation to evaluation to interpretation and finally to dissemination. ISPOR can take a leadership role in identifying and promoting "best practices" for stakeholder engagement.
It would be an honor for me to serve as President of ISPOR to further our collective vision for the Society to improve worldwide health.
– – – – – » TOP
Josephine Mauskopf, PhD
Josephine Mauskopf, PhD, is Vice President of Health Economics at RTI Health Solutions. She has Master's degrees in Physiology/Pharmacology and in Health Administration and a PhD in Economics all from Duke University. She has spent the last 30 years working both in the pharmaceutical industry and as a consultant. Her consulting experiences include health benefits assessments for toxic substance regulations for the US Environmental Protection Agency and for food safety regulations for the US Food and Drug Administration. For the pharmaceutical and medical device industry she has developed strategic plans for economic evaluations of new products and estimated the burden of illness and developed cost-effectiveness and budget impact models for drugs in many therapeutic areas. Therapeutic areas of special focus have been infectious diseases and neurologic conditions. She is an author of more than 100 peer-reviewed publications as well as book and encyclopedia chapters. She has been especially active in the development of methods for performing budget impact analyses.
Dr. Mauskopf has been a member of ISPOR since 1997. She served for 2 years as a co-editor and 8 years as Editor-in-Chief of the ISPOR journal, Value in Health, and was co-chair of both the first and second ISPOR Budget Impact Analysis Task Forces. She also served as a member of the ISPOR Reporting Guidelines Task Force and the Conjoint Analysis Task Force. She has taught the ISPOR Short Course on budget impact analysis at both the ISPOR Annual International Meetings and European Congresses for over 10 years. In 2006 she received the ISPOR Excellence in Application of Pharmacoeconomics and Health Outcomes Research Award for a paper presenting an HIV cost-effectiveness model and, in 2013, she received the ISPOR Avedis Donabedian Lifetime Achievement Award for her many contributions to the profession.
ISPOR Vision Statement by Josephine Mauskopf, PhD
I am excited about the opportunity to take an active role on the ISPOR Board at this time of transition for the Society.
I believe that one of the most important characteristics of ISPOR has been that it offers all members the opportunity to participate in fulfilling the mission and vision of the Society. Members from around the globe take active leadership roles through various ISPOR Task Forces, SIGs, Councils, Round Tables, Regional Groups, and Student Chapters. Collectively, members support new methods development, develop data and tools for decision makers, and encourage the exchange of research results and ideas about methods and policies at ISPOR meetings and in other professional forums. The creative energy generated at each meeting by the active participation of so many people is invigorating to me.
I want to combine your creative energy with my experience in ISPOR, the industry and consulting to serve you, the members of ISPOR, as a Board member.
My goals as a Board member would be to foster:
- Continued success and growth – to ensure that ISPOR continues to provide all its members with new opportunities to grow as individuals, researchers, and influencers of health care decisions
- Research that decision makers use – to ensure that ISPOR continues with its efforts to make economic evaluations more transparent to all health care decision makers including the payer, the practitioner and the patient
- Global development of methods to assess drug/device value – to encourage ISPOR to support the development and application of methods that reflect individual markets' specific needs and realities
- Innovative methods to assess the affordability of new interventions – to encourage ISPOR to address the realities of budget constraints and opportunity costs of innovative interventions
– – – – – » TOP
Director (2014-2016): Karen Worley, PhD
Karen Worley, PhD, leads the internal research team for Comprehensive Health Insights (CHI), a wholly owned subsidiary of Humana, Inc. She has a PhD in Epidemiology and Biostatistics and MS in Preventive Medicine from the Ohio State University, and a BA in Sociology from Miami University. Prior to joining CHI in 2010, she spent 10 years in the Pharmacoeconomics, Epidemiology, and Biostatistics Division at Procter & Gamble Pharmaceuticals and Warner Chilcott Pharmaceuticals. She has conducted and managed a wide range of observational and interventional studies, including retrospective claims database studies, prospective survey research, and post-marketing (Phase IV) studies.
In her current role at CHI/Humana, Dr. Worley oversees the portfolio of internal research initiatives that are used to support health plan decisions in regard to both pharmaceutical products and medical interventions. She is especially interested in drug safety and efficacy in the post-marketing setting, and research that provides insight to healthcare organizations as they strive to improve patient care and outcomes. An active member of ISPOR, she has been heavily involved in the Comparative Effectiveness Research Collaborative Initiative (CER-CI) between ISPOR, the Academy of Managed Care Pharmacy (AMCP), and National Pharmaceutical Council (NPC), in which her task force designed a tool to assist decision-makers in assessing the relevance and credibility of observational comparative-effectiveness studies.
Dr. Worley is the Chair of the Editorial Advisory Board for the Journal of Managed Care Pharmacy, and serves as a reviewer for a several other health sciences journals. She has published and presented her research in a variety of clinical, surgical, and managed-care oriented journals and conferences.
ISPOR Vision Statement by Karen Worley, PhD
ISPOR's growth and successful development into a highly-regarded international organization is in large part due to its self-awareness and keen understanding of the changing forces that mold our healthcare environment. The current global healthcare landscape emphasizes the importance of "integrated delivery models" in patient care. Often this is operationalized as sharing the patient's health information from one setting to the next, encouraging dialogue and communication across various providers, and building efficiencies to be leveraged across networks of care. However, a necessary and often understated component of a successfully integrated system is the integration of evidence into the model of care. The patient expects that the individuals making decisions around his or her care are doing so based on sound scientific principles supported by a strong body of research. But in this era of high-cost health care and limited resources, do providers and other decision-makers have this information at their disposal? Are they interpreting and using it correctly? Can they identify the research of highest value in making their decision? In truth, a healthcare delivery system cannot truly be considered "integrated" if the decisions being made in that system are not integrating the appropriate evidence.
I see ISPOR as being instrumental in this space, serving the public not only by continuing to develop those researchers who produce the evidence, but also advocating for tools and systems that leverage the evidence and assuring that it is used appropriately throughout the healthcare system. As part of its Vision 2020 Strategic Plan, ISPOR has identified many external groups, organizations, and individuals and begun to work collaboratively in order to advance evidence-based healthcare decision-making. Research, education, and communication are necessary to achieve our goals, and true integration is the ultimate measure of success. I believe that we, as an organization, need to continue in this direction, and to fully immerse ourselves in this "integrated" model of evidence production, dissemination, and utilization.
– – – – – » TOP
Director (2014-2016): Yen-Huei (Tony) Tarn, MS, PhD
Yen-Huei (Tony) Tarn, MS, PhD is currently Executive Director of Center for Pharmaceutical Care Development of the Taiwan Pharmacist Association responsible for the training, planning and implementation of home care services provided by the Taiwanese pharmacists. He was an Associate Professor at School of Pharmacy, National Defense Medical Center (NDMC) from 1980 to 2004; Director General of the Department of Pharmacy at Taipei City Hospital from 2005 to 2006, responsible for ten branches pharmacy operation; Chairman of the School of Pharmacy at Taipei Medical University; and Director of Division of Health Technology Assessment (HTA) at Center for Drug Evaluation from 2007 to 2009.
Dr. Tarn was the President of Taiwan Society for Pharmacoeconomics and Outcomes Research (TaSPOR) from 2005-2008 and currently serves as Director on the Executive Board of TaSPOR. He is also the Deputy Chair of the Executive Board Member of the Western Pacific Pharmaceutical Forum (WPPF) of the Federation International Pharmaceutical (FIP) since 2005.
Dr. Tarn's major interests include pharmaceutical care practice, economic evaluation of new drugs and clinical services, quality of life measurement, establishing new platforms for pharmacists to practice, reimbursement decision-making and the impact of reimbursement policies on clinical practice, especially new drugs, and pharmaceutical care at home and long-term care settings. He graduated from School of Pharmacy, National Defense Medical Center, Taipei, Taiwan in 1980 with a BS degree in pharmacy; and a MS degree from College of Pharmacy, The University of Iowa, Iowa City, USA in 1986, where he focused on clinical / hospital pharmacy. In 1993, he obtained his PhD degree in Pharmacy Administrative and Behavioral Science from the College of Pharmacy, The University of Arizona, Tucson, Arizona.
ISPOR Vision Statement by Yen-Huei (Tony) Tarn, MS, PhD
In Asia Pacific region, health technology assessment is becoming increasingly important in health care reimbursement decisions, different stakeholders within this area still lack an understanding of the value of pharmacoeconomics and outcomes research, in health technology assessment and its use in health care decisions. ISPOR members have the knowledge and tools to help decision-makers understand the changes in health care reimbursement systems around the world and the use of pharmacoeconomics and outcomes research in these decisions. Therefore, educating health care decision-makers in national health insurance programs, hospital administrators, clinicians and patient groups will be a major task for ISPOR in the near future. The resources on the ISPOR website and the skills, insights, and experiences of ISPOR members should facilitate this educational process. Also, collaboration with WHO on capacity building is very important.
My vision for ISPOR centers on education and patient involvement in health care decision making process. We need to encourage more government officials to participate as members in ISPOR. In each country, we need to create HTA capacity building fellowship program, encourage the use of PE & OR evidences in national health insurance policies on pricing and reimbursement. Treatment guidelines based on this evidence is very important to create incentives for industry to invest revenue to conduct the research. We need to encourage clinicians and professors to focus on pharmacoeconomics and outcomes research and graduate students to become familiar with this discipline and conduct outcomes research. We need patient groups to act as patient advocate and provide patient evidences into the healthcare decision making process. To achieve this, ISPOR may need to give more incentives to country chapters to establish training programs for capacity building and patient involvement. At the same time, I would devote myself to effectively communicate all the information from ISPOR to WHO, payers, policy makers and the patient groups through Asia Consortium and to promote effective ways of communicating with decision-makers at all levels in the Asia countries.
– – – – – » TOP
Director (2014-2016): Dominik Tomek, MPH, PharmD, PhD
Dominik Tomek, MPH, PharmD, PhD, has experience in public and hospital pharmacies, government administration and regulatory agency including oncology hospital, the Slovakia Ministry of Health and Health Insurance. He is a founding member of the Slovak Society for Pharmacoeconomics, founding member and former director of Slovak Agency for Health Technology Assessment and a founding member and President-elect of the ISPOR Slovakia Chapter as well as member of ISPOR Central & Eastern Europe Network.
Dr. Tomek served for many years in the Drug Committee of State Institute for Drug Control, Pricing Committee of Ministry of Finance, in several Health Insurance Funds and Reimbursement Committee of Ministry of Health. He teaches at the Faculty of Medicine, Slovak Medical University and Faculty of Pharmacy, Comenius University, Bratislava, Slovakia. Dr. Tomek has a doctor degree in clinical pharmacy, a PhD. in the field of public health and degrees of postgraduate specializations in management of public pharmacy, preparation of radiopharmaceuticals, revision pharmacy for health insurance, pharmacoeconomics and in management of public health. In 2011-2012 he finished his study at the University Lyon, France, with a European Market Access Diploma.
He pioneered a Patient Empowerment and Patient Education initiative in Slovakia. Since 2010 he is teaching, training and lecturing patients in the field of treatment adherence, prevention, communication, health economy and other drug policy and health policy issues. He initiated patient education at the Faculty of Medicine, where he is supervising this education. He initiated and supervised several patient-reported outcomes studies in Slovakia. He is a patient himself, a patient relative, a long time health care provider including many years in an oncology institute, and a dedicated patient advocate.
ISPOR Vision Statement by Dominik Tomek, MPH, PharmD, PhD
I have supported the vision and mission of the Society since its early days, and I am honored to be a candidate for an ISPOR Director position. My vision is that ISPOR must expand further in the regions by providing support and empowerment to the ISPOR regional chapters to engage directly with the patients, to tackle their daily life and health outcome issues. The ultimate goal should not only be to serve the science and health care evidence generation, but to serve the people. There is a need to promote local outcomes research, especially patient-reported outcomes research. There is a need for the implementation of evidence-based health policy in daily practice in smaller countries in emerging regions. There is still unlocked potential for ISPOR with members from ROW countries. The Society has already made important steps into this direction by establishing regional chapters, facilitating regional conferences and launching a new regional journal. Regardless of the outcome of my candidacy I am dedicated to support the visions of ISPOR in the future.
– – – – – » TOP